<DOC>
	<DOCNO>NCT01106534</DOCNO>
	<brief_summary>XIENCE V USA prospective , multi-center , multi-cohort postapproval study . The objective study - To evaluate XIENCE V EECSS continue safety effectiveness commercial use real world setting , - To support Food Drug Administration ( FDA ) dual antiplatelet therapy ( DAPT ) initiative . This initiative design evaluate composite death , myocardial infarction ( MI ) stroke ( MACCE ) survival patient free Academic Research Consortium ( ARC ) definite probable stent thrombosis ( ST ) treat drug elute stent ( DES ) extend dual antiplatelet therapy .</brief_summary>
	<brief_title>XIENCE V® USA Dual Antiplatelet Therapy ( DAPT ) Cohort</brief_title>
	<detailed_description>This prospective , multi-center , randomize , double-blind AV-DAPT study cohort design collect data support FDA DAPT initiative . The protocol AV-DAPT cohort design accord HCRI-DAPT ( NCT00977938 ) study protocol , Study IDE # G080186 . A total 8040 patient ( 5034 initial enrollment phase additional ~3000 patient second enrollment phase ) enrol XIENCE V USA ( NCT00676520 ) complete Phase I evaluate 1 year . These patient transfer follow cohort Phase II followed-up 1-5 year : The long-term follow-up cohort phase II ( NCT01120379 ) consist 5020 patient first enrollment phase transfer HCRI- DAPT study remain study beyond 1 year . Patients additional 3000 treat XIENCE V EECSS free event ( death , MI , repeat coronary revascularization , stroke , ST , major bleed - `` severe '' `` moderate '' GUSTO classification ) first year index procedure , compliant DAPT identify prospective patient AV-DAPT cohort . A total 870 Patients consider part AV-DAPT cohort continue Aspirin therapy randomize 12 month post index procedure 18 month either active treatment thienopyridines placebo . Clinical follow-up occur 15 , 24 , 30 33 month . These patient follow Abbott Vascular . The remain patient additional 3000 patient participate AV-DAPT cohort follow first year . A study completion form fill patient follow beyond 1 year visit . The participant enrol study follow Abbott Vascular data independently analyze ; analyze part DAPT study ( NCT00977938 ) sufficiently power study outcome .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients enrol XIENCE V USA Study Phase I The patient agree participate study sign Institutional Review Board ( IRB ) approve informed consent form . Alternatively , patient 's legally authorize representative agrees patient 's participation study sign inform consent form . The inability obtain informed consent exclusion criterion . Patients must meet follow criterion eligible randomization study : Patient `` 12 Month Clear '' : `` 12Month Clear '' patient free death , MI , stroke , repeat coronary revascularization , major bleed `` severe '' `` moderate '' GUSTO classification , ST 12 month stent implantation . Staged PCI allow ( stent type index ) ; repeat PCI periprocedural myocardial infarction occur index procedure repeat procedure within first 6 week consider exclusionary event definition `` 12 Month Clear '' . Patient `` DAPT Compliant '' : During open label portion study ( time 012 month ) , patient consider compliant thienopyridine therapy purpose eligibility take 80 % 120 % prescribed drug give period without interruption therapy longer 14 day . This information ascertain via data collect patient interview 6 12 month postprocedure . Compliance time point require consider `` clear '' . Patient complete 1 year visit within ± 30 day window . Patients exclude randomization follow criterion meet : Pregnant woman . Switched thienopyridine type dose within 6 month prior randomization . Note : Thienopyridine switch open label portion study discourage . PCI cardiac surgery 6 week post index procedure randomization . Planned surgery necessitate discontinuation antiplatelet therapy within 21 month follow randomization . Current medical condition life expectancy le 3 year . Patients warfarin similar anticoagulant therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>drug elute stent</keyword>
	<keyword>Stents</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Stent thrombosis</keyword>
	<keyword>antiplatelet treatment</keyword>
</DOC>